These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12846440)

  • 21. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.
    Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
    Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
    Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate.
    Kang WS; Lim IH; Yuk DY; Chung KH; Park JB; Yoo HS; Yun YP
    Thromb Res; 1999 Nov; 96(3):229-37. PubMed ID: 10588466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the antithrombotic and antiplatelet activities of NQ304, a newly synthesized naphthoquinone derivative.
    Yuk DY; Lee HY; Ryu CK; Hong JT; Kang WS; Yoo HS; Yun YP
    Arzneimittelforschung; 2000 Mar; 50(3):254-9. PubMed ID: 10758777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration.
    Kjalke M; Oliver JA; Monroe DM; Hoffman M; Ezban M; Hedner U; Roberts HR
    Thromb Haemost; 1997 Oct; 78(4):1202-8. PubMed ID: 9364985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets.
    Karmohapatra SK; Chakraborty K; Kahn NN; Sinha AK
    Am J Hematol; 2007 Nov; 82(11):986-95. PubMed ID: 17636472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.
    Sakariassen KS; Hanson SR; Cadroy Y
    Thromb Res; 2001 Nov; 104(3):149-74. PubMed ID: 11672758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties.
    Dutra LA; Guanaes JFO; Johmann N; Lopes Pires ME; Chin CM; Marcondes S; Dos Santos JL
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2450-2453. PubMed ID: 28400236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of ADP-induced platelet aggregation and involvement of non-cellular blood chemical mediators are responsible for the antithrombotic potential of the fruits of Lagenaria siceraria.
    Rajput MS; Balekar N; Jain DK
    Chin J Nat Med; 2014 Aug; 12(8):599-606. PubMed ID: 25156285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonist.
    Bernat A; Hoffmann P; Savi P; Lalé A; Herbert JM
    J Cardiovasc Pharmacol; 1999 Jun; 33(6):897-904. PubMed ID: 10367593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
    Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model.
    Priya N; Singh P; Bhatia S; Medhi B; Prasad AK; Parmar VS; Raj HG
    J Pharm Pharmacol; 2011 Sep; 63(9):1175-85. PubMed ID: 21827490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in combination with ASA, pentoxifylline, and ticlopidine.
    Rehse K; Ciborski T
    Arch Pharm (Weinheim); 1995 Jan; 328(1):71-8. PubMed ID: 7695475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans.
    de la Cruz JP; Guerrero A; González-Correa JA; Márquez E; Nacle I; Sánchez de la Cuesta F
    Eur J Clin Pharmacol; 2002 Jan; 57(11):775-80. PubMed ID: 11871383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN; Sauermelch CF; Rycyna R; Sarkar S; Feuerstein GZ; Nichols AJ; Ohlstein EH
    Stroke; 1992 May; 23(5):703-11. PubMed ID: 1605806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative.
    Jin YR; Hwang KA; Cho MR; Kim SY; Kim JH; Ryu CK; Son DJ; Park YH; Yun YP
    Vascul Pharmacol; 2004 Feb; 41(1):35-41. PubMed ID: 15135330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.